A 67-year-old man with AML, who had a 21-year history of psoriasis without remission, received a reducedintensity transplantation from an HLA-identical sibling. The preparative regimen consisted of busulfan and fludarabine. Graft-versus-host-disease (GVHD) prophylaxis was cyclosporine and methotrexate. Psoriasis was completely resolved on day 18. The subsequent clinical course was uneventful until day 42, when psoriasis recurred at the same sites as before RIST. Peripheral blood examined on day 63 showed mixed chimerism with 54% recipient type. Cyclosporine was rapidly tapered off over the next 2 weeks. On day 90, 100% donor-type chimerism was confirmed. Subsequently, psoriasis improved simultaneously with the occurrence of mucositis and rash as a manifestation of GVHD. Scattered erythematous patches of psoriasis disappeared again by day 105. We initiated 0.5 mg/kg prednisolone on day 119, and resumed cyclosporine on day 133. At 7 months after RIST, he still suffers from chronic GVHD, but his psoriasis remains in remission for the first time in 21 years. The anti-psoriasis effect of the conditioning is mild and transient, while the graft-versus-autoimmunity effect, related to the induction of complete donor-type chimerism and GVHD, is more profound and persisting. A graftversus-autoimmunity effect lies in the delicate balance between alloimmunity and immunosuppressant used for GVHD prophylaxis/treatment. Bone Marrow Transplantation (2003) 32, 439-442. doi:10.1038/sj.bmt.1704146 Keywords: reduced-intensity stem cell transplantation; psoriasis; graft-versus-autoimmunity effect; graft-versushost disease Autologous stem cell transplantation (auto-SCT) has attracted attention for the treatment of severe lifethreatening autoimmune diseases, which include a stem cell disorder as a component. The background concept is that ablation of the diseased immune system followed by hematopoietic reconstitution with self-stem cells should restore normal immunity without attacking self-epitopes. Long-term remission and improvement have been observed in some cases after auto-SCT against autoimmune diseases.
psoriasis; graft-versus-autoimmunity effect; graft-versushost disease Autologous stem cell transplantation (auto-SCT) has attracted attention for the treatment of severe lifethreatening autoimmune diseases, which include a stem cell disorder as a component. The background concept is that ablation of the diseased immune system followed by hematopoietic reconstitution with self-stem cells should restore normal immunity without attacking self-epitopes. Long-term remission and improvement have been observed in some cases after auto-SCT against autoimmune diseases. [1] [2] [3] [4] [5] [6] Although auto-SCT has fewer toxicities and complications than allo-SCT, it is limited by the common recurrence of the primary diseases, especially in recipients of unmanipulated autografts. On the other hand, allo-SCT has been used to treat fatal disorders, both malignant and nonmalignant, as a curative approach. Theoretical graftversus-autoimmunity (GVA) effects due to the activation and reconstitution of donor T cells also support the effectiveness of allo-SCT against autoimmune diseases.
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However, its significant treatment-related mortality has limited its application to life-threatening cases.
Reduced-intensity stem cell transplantation (RIST), a new transplantation method with nonmyeloablative preparative regimens, has been developed to reduce regimenrelated toxicity (RRT) without spoiling the antitumor effect of allo-SCT. 8 The safety and efficacy of RIST have been demonstrated at our institution, with a 1-year nonrelapse mortality rate of only 7% in patients (age; median 52 years, range 4-52) with hematological and solid malignancies (unpublished data). The reported transplantation-related mortality for all autoimmune diseases has been 8.6%, which is higher than expected because of phase I trials that selected patients with advanced end-organ dysfunction and/or active and refractory disease. 2 Although the data cannot be directly applied to patients with autoimmune diseases and comorbidities, the safety of RIST would be preserved in patients with autoimmune diseases unless they are complicated with organ dysfunction or comorbidities. Hence, it is possible that RIST may be a promising treatment modality against severe autoimmune diseases.
We report here a case of long-lasting active psoriasis, which achieved remission for the first time concomitantly with RIST against acute myeloblastic leukemia (AML). He was free of comorbidities except for the hematological disorder and skin rash. The patient's psoriasis notably improved with the achievement of complete donor-type chimerism and the manifestation of GVHD ( Figure 1 ).
Case report
A 67-year-old Japanese man with AML in second remission was admitted to our hospital for RIST from an HLA-matched sibling in April 2002. Neither the recipient or the donor had HLA B27. He had a 21-year history of moderate cutaneous psoriasis, which had never reached remission even with multiple treatment trials, including topical and systemic corticosteroids, vitamin D and PUVA. Physical examination on admission revealed pruritic, wellcircumscribed, thickened, scaly plaques on lesions on his skull, face, forehead, neck, fingers, chest, back, elbows, buttocks, ankles, knees and thighs ( Figure 2 ). His psoriasis was moderate according to the Psoriasis Area and Severity Index. 9 He received busulfan (4 mg/kg/day, days À6 and À5) and fludarabine (25 mg/kg/day, from days À8 to À3), followed by the infusion of G-CSF-mobilized peripheral blood stem cells without CD34+ selection. The CD34+ cells in the graft were 2.1 Â 10E6/kg. Immediately after the initiation of fludarabine, the skin lesions started to regress, and they completely disappeared by the day of transplantation, leaving only keratotic scars. GVHD prophylaxis consisted of cyclosporine 3 mg/kg/day and short-term methotrexate. His clinical course was uneventful except for the development of severe oral mucositis. Engraftment was as early as day 16, with absolute neutrophil counts 4500/ml and platelet counts 420,000/ml. Quantitative polymerase chain reaction of microsatellite markers showed mixed chimerism with 60% recipient's cells on day 27. The patient was discharged on day 34 of transplantation with wellcontrolled psoriasis.
On day 42, the patient was readmitted to the hospital for hyperkalemia attributed to trimethoprim-sulfamethoxazole, and recurrence of psoriasis with scaling erythematous lesions noted at the same sites as before transplantation (Figure 3) . Whereas AML remained in complete remission (CR), peripheral blood showed mixed chimerism with 54% recipient type on day 63. Given the high risk of graft rejection, cyclosporine was rapidly tapered off on day 91, and complete donor type (100%) was confirmed on day 90. Subsequently, mucositis and diffuse maculopapular rash, as a manifestation of GVHD, developed in parallel with the improvement of psoriasis. The erythematous patches with silvery scales continued to regress, and completely disappeared by day 105. The patient had refused skin biopsy until day 119 when skin biopsy was compatible with GVHD without signs of psoriasis.
Chronic GVHD progressed to the eyes, oral mucosa, skin, and liver, leading to the initiation of prednisolone 0.5 mg/kg on day 119 and cyclosporine 50 mg on day 133. GVHD gradually improved without relapse of AML. Psoriasis has remained under control since the development of chronic GVHD, while the patient's ECOG performance status was 0 as of November 2002, 7 months after RIST.
Discussion
Whether complete chimerism is definitely required or mixed chimerism is sufficient in the control of autoimmune Figure 1 The changing clinical course of psoriasis. A transient response of psoriasis was observed following the conditioning chemotherapy. Recurrence of psoriasis was concomitant with immunosuppression and mixed chimerism (recipient-type dominant). Since the rapid tapering of cyclosporine successfully induced complete chimerism, psoriasis regressed in concert with the development of acute GVHD. Abbreviations: RIST, reduced intensity stem cell transplantation; GVHD, graft-versus-host disease; CyA, cyclosporine; PSL, prednisolone. reported a psoriasis response with 30-40% mixed chimerism, most previous reports have suggested that complete chimerism is needed to suppress autoimmune diseases. Adkins et al 11 reported a case in which psoriasis rapidly responded after CST against chronic myelogenous leukemia (CML), and remission continued for 2.4 years in concert with complete chimerism and significant GVHD. Slavin et al 7 experienced a case with a course similar to ours; 7 psoriasis was under control during the period of near-complete chimerism with only a trace presence of host DNA after RIST for CML, and recurred on day 32 when chimerism decreased to 70% recipient type and cytogenetic relapse of CML was noted. Discontinuation of cyclosporine to induce GVHD resulted in complete chimerism and psoriasis remission. In the present case, psoriasis improved immediately with the RIST conditioning regimen, but soon recurred. Only when complete chimerism was induced with rapid tapering of cyclosporine did psoriasis attain durable remission. These observations support the notion that conditioning chemotherapy induces a prompt but transient response, whereas allogeneic immunity is more profound and durable. While the treatment for the primary malignancy may have improved psoriasis, this is unlikely given the history of long-standing, refractory psoriasis prior to RIST.
Allogeneic T cells attack the skin, liver, and gut, which is known as GVHD, and the strongest allogeneic immune response occurs against the lymphohematopoietic system. In the murine model, the graft-versus-host response that follows infusions of donor leukocytes is confined to the lymphohematopoietic space and does not injure epithelial tissue. 12 Malignancies of mature B cells, which are derived from lymphohematopoietic tissues, are particularly sensitive to a GVL effect as reported with RIST: all 20 patients with indolent lymphoma achieved CR, 13 72% of 22 patients with multiple myeloma showed a response, 14 and mature B-cell malignancies were associated with a better prognosis. 15 Autoimmune diseases are likewise disorders of mature lymphocytes, 16 and have been speculated to be sensitive to a GVA effect of allogeneic grafts, where mixed chimerism without GVHD would be sufficient to control autoimmune diseases.
Complete chimerism, however, is probably required for the suppression of autoimmune disorders, as shown in the present and previous observations, which supports the idea that autoimmune diseases are not as sensitive to alloimmunity as indolent lymphoma. 7, 11 Significant acute and chronic GVHD in CST can lead to the durable remission of psoriasis, but may also cause the death of patients. Severe, sometimes lethal, GVHD, or the introduction of another immune dysfunction to HSCT recipients, should be avoided in the treatment of benign autoimmune disorders. Hence, more intense GVHD prophylaxis may become a reasonable option. T cell depletion and/or intense immunosuppression also reduce the frequency and severity of GVHD. Although the intensification of GVHD prophylaxis can ensure a safer transplantation procedure, this sometimes results in a high relapse rate in allo-HSCT against hematological malignancies. Excessive GVHD prophylaxis may also not be beneficial in the long-term control of autoimmune diseases. The optimal GVHD prophylaxis or conditioning regimens, which enable the maintenance of alloimmunity in RIST within the narrow window between GVHD and complete chimerism, or safety and effectiveness, should be established in the setting of allo-HSCT for autoimmune diseases.
Some researchers believe that RIST is a promising treatment option for autoimmune disorders. However, since patients with autoimmune diseases are not at an imminent risk of death, severe GVHD should be avoided. Further investigation is required to establish a safe RIST procedure without GVHD, and to clarify its effectiveness against autoimmune disorders.
